Haloperidol decanoate

Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model^[1][4]. In Vivo:Haloperidol decanoate (38 mg/kg, i.m., single dose) increases the gene expression of pro-inflammatory cytokines, COX-2 and iNOS^[2].
[¹⁴C]haloperidol decanoate (34.25 mg/0.18 ml of sesame oil containing 1.5% benzyl alcohol, i.m., single dose) showed the highest levels of total radioactivity and haloperidol decanoate (HD) in examined lymph nodes and plasma in male Wistar rats^[3].
Haloperidol decanoate (Compound HPD-D) (100 mg/kg, s.c., single dose) significantly increases the B_max of [³H]spiperone binding in the striatum in rat model^[4].